Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celebrex Needs To Prove GI Safety Advantage Over Ibuprofen - HRG's Wolfe

Executive Summary

Searle/Pfizer's Celebrex should not be able to claim increased gastrointestinal safety over other NSAIDs until a clear safety advantage over ibuprofen is proven, Public Citizen's Health Research Group Director Sidney Wolfe, MD, told FDA's Arthritis Drugs Advisory Committee meeting on celecoxib Dec. 1.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS033241

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel